800 mg + 160 mg, tablets
Sulfamethoxazole + Trimethoprim
Bactrim Forte has antibacterial effects. It contains the active substances: sulfamethoxazole and trimethoprim. The combination of these two substances is known as co-trimoxazole.
Before recommending the use of the medicine, the doctor will consider the susceptibility of the microorganisms causing the infection and the possibility of side effects.
The therapeutic indications are limited to infections caused by microorganisms susceptible to the medicine.
Bactrim Forte should be used for the treatment or prevention of infections, only in cases where it has been confirmed or there is a justified suspicion that they were caused by bacteria or other microorganisms susceptible to the active substances of this medicine. In the absence of such data, in the process of selecting the appropriate antibiotic therapy, local epidemiological conditions and antibiotic resistance of microorganisms should be taken into account.
Bactrim Forte is indicated for the treatment of adults and adolescents over 12 years of age.
Indications for use:
Pulmonary infiltrates observed in connection with eosinophilic or allergic pneumonia may manifest as cough and shortness of breath. If these symptoms occur or worsen suddenly, the patient should see a doctor.
Hemophagocytic lymphohistiocytosis
Very rare cases of severe immunological reactions resulting from uncontrolled activation of white blood cells, leading to inflammatory conditions (hemophagocytic lymphohistiocytosis) have been reported — they can be life-threatening if not diagnosed and treated early. If multiple symptoms occur simultaneously or with a slight delay, such as fever, lymph node swelling, weakness, dizziness, shortness of breath, cyanosis, or skin rash, the patient should immediately contact their doctor.
Effect on the kidneys
Sulfonamides, including Bactrim Forte, may cause increased urine excretion, especially in patients with heart failure.
The doctor should carefully monitor the potassium level in the blood serum and kidney function in patients:
If the patient has a folic acid deficiency, they may experience blood-related side effects. These symptoms disappear after folic acid administration.
Bactrim Forte should not be used in patients with G6PD enzyme deficiency, except in cases of absolute necessity. In such cases, only minimal doses of the medicine should be used.
In patients with renal impairment, the doctor will recommend a dose adjusted for the individual patient based on the results of tests (creatinine clearance), see section 3.
The medicine should be used with caution. The doctor will order more frequent blood tests.
Bactrim in the form of a syrup with a strength of (200 mg + 40 mg)/5 ml is mainly intended for use in children under 12 years of age.
See section 3.
In patients with folic acid deficiency (in elderly patients, patients with pre-existing folic acid deficiency, or patients with renal impairment), blood-related side effects occur more frequently. These symptoms disappear after folic acid administration. The doctor will order periodic blood tests.
The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take. The doctor will decide on the continuation, possible modification, and monitoring of treatment effects. This applies in particular to medicines containing:
In the case of the patient taking the above-mentioned medicines, the doctor will decide whether the patient can take Bactrim Forte at the same time.
It is not recommended to use Bactrim Forte concomitantly with medicines containing:
The frequency and severity of side effects such as bone marrow damage and kidney damage may increase if Bactrim Forte is administered concomitantly with other medicines that have a proven effect on reducing the number of bone marrow cells or are harmful to the kidneys), such as nucleoside analogs(used in antitumor and antiviral therapy), tacrolimus(used to prevent transplant rejection), azathioprine(a medicine that inhibits the activity of the immune system), or mercaptopurine(an anticancer and immunosuppressive medicine).
Effect on laboratory test results
The patient should inform their doctor about taking Bactrim Forte if it is necessary to determine the creatinine or methotrexate level in the blood. The doctor will order a laboratory test using an appropriate method.
If the patient is pregnant or breastfeeding, suspects they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before taking this medicine. The doctor will consider the use of Bactrim Forte in pregnant or breastfeeding women. There is no conclusive evidence of the risk of fetal malformations in women treated with co-trimoxazole in early pregnancy. However, an increased risk of spontaneous abortion has been observed in women who took trimethoprim or trimethoprim in combination with sulfamethoxazole in the first trimester of pregnancy. Animal studies indicate that very high doses of co-trimoxazole can cause fetal malformations typical of folic acid-lowering substances.
The medicine may be used during pregnancy only if the expected benefits of treatment outweigh the potential risk to the fetus. In such cases, pregnant women or women planning to become pregnant during treatment with Bactrim Forte are recommended to take folic acid at a dose of 5 mg per day. Whenever possible, the use of Bactrim Forte should be avoided in the last period of pregnancy due to the risk of kernicterus in the newborn. Since the active substances of Bactrim Forte pass into breast milk, the doctor will consider the risk to the child (kernicterus, hypersensitivity) in relation to the expected therapeutic benefits for the mother.
There is no available data on the effect on fertility.
There is no data on the effect of the medicine on the ability to drive and use machines.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means that the medicine is considered "sodium-free".
This medicine should always be taken according to the doctor's recommendations. In case of doubts, the patient should consult their doctor.
Bactrim Forte is taken orally. The tablet can be divided into equal doses.
It is best to take it after a meal with a sufficient amount of fluids.
Adults and adolescents over 12 years of age with normal kidney function
In the case of acute infections, Bactrim Forte is administered for at least 5 days or until the patient has not shown symptoms of infection for at least 2 days. If there is no clinical improvement after a week of treatment, the patient should see their doctor again.
Pneumonia caused by Pneumocystis jirovecii
A dose not exceeding 100 mg/kg body weight per day of sulfamethoxazole and 20 mg/kg body weight per day of trimethoprim is used, in equal doses divided and administered every 6 hours, for 14 days.
Maximum doses depending on the patient's body weight with pneumonia caused by Pneumocystis jirovecii.
Dose - taken every 12 hours | Number of Bactrim Forte tablets |
Usually used | 1 |
High, in severe infections | 1 and ½ |
Minimum, in long-term treatment | ½ |
Body weight [kg] | Number of Bactrim Forte tablets administered every 6 hours |
16 |
|
24 |
|
32 | 1 |
40 |
|
48 | 1 and ½ |
64 | 2 |
80 | 2 and ½ |
*To achieve the appropriate maximum dose, the doctor will recommend the use of Bactrim, 400 mg + 80 mg, tablets, or Bactrim, (200 mg + 40 mg)/5 ml, syrup.
In the prophylaxis of pneumonia caused by Pneumocystis jirovecii, the recommended dose in adolescents and adults is 1 tablet of Bactrim Forte once a day. The results of a study conducted in patients infected with HIV also indicate the effectiveness of using ½ tablet of Bactrim Forte once a day.
Single-dose treatment in uncomplicated, acute urinary tract infections
2 to 3 tablets of Bactrim Forte taken once, preferably in the evening after dinner or before bedtime.
Treatment of soft chancre
1 tablet of Bactrim Forte twice a day. If there are no visible signs of improvement after 7 days, the doctor will consider administering the medicine for another 7 days.
Dosing in patients with renal impairment
Recommended dosing regimen in patients with renal impairment:
Creatinine clearance > 30 ml/min: standard dosing.
Creatinine clearance 15 – 30 ml/min: half of the standard dose.
Creatinine clearance <15 ml min: bactrim forte should not be used (see section 2).
Dosing in patients undergoing dialysis
Patients undergoing hemodialysis should initially receive a normal loading dose of the medicine and then an additional half dose after each hemodialysis. Peritoneal dialysis results in minimal removal of the medicine. It is not recommended to use the medicine in patients undergoing peritoneal dialysis.
Dosing in elderly patients
In elderly patients with normal kidney function, the same doses as in adults should be used.
In case of any further doubts related to the use of this medicine, the patient should consult their doctor or pharmacist.
Like all medicines, Bactrim Forte can cause side effects, although not everybody gets them.
In the recommended doses, Bactrim Forte is generally well-tolerated.
Common side effects (occurring in less than 1 in 10 patients, but more than 1 in 100 patients) are:
Uncommon side effects (occurring in less than 1 in 100 patients) are:
Rare side effects (occurring in less than 1 in 1,000 patients, but more than 1 in 10,000 patients) are:
Very rare side effects (occurring in less than 1 in 10,000 patients) are:
Side effects with an unknown frequency (cannot be estimated from the available data) include:
Safety in patients infected with HIV
The types of side effects in this patient group are similar to those observed in the general population of patients taking Bactrim Forte. However, some side effects may occur more frequently and have a different clinical picture. These differences concern the following symptoms:
Very common:
decrease in the number of certain types of blood cells (leukopenia, granulocytopenia, and thrombocytopenia);
increased potassium levels in the blood (hyperkalemia);
anorexia, nausea with or without vomiting, diarrhea;
papular rash, itching;
fever, usually accompanied by a papular rash;
increased liver enzyme activity (aminotransferases).
Uncommon:
decreased sodium (hyponatremia) or glucose (hypoglycemia) levels in the blood.
If side effects occur, including any not listed in the leaflet, the patient should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products,
Al. Jerozolimskie 181C 02 - 222 Warsaw Tel.: + 48 22 49 21 301 Fax: + 48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
There are no special recommendations for storage.
The medicine should not be used after the expiry date stated on the packaging. The expiry date refers to the last day of the specified month.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
White or almost white, oblong, biconvex tablet with dimensions of approximately 19x9 mm with the inscription "BACTRIM 800+160" on one side and a dividing line on the other. The tablet can be divided into equal doses.
The packaging contains 10 tablets in a blister pack, in a cardboard box
For more detailed information, the patient should contact the marketing authorization holder or parallel importer.
EUMEDICA Pharmaceuticals GmbH
Basler Straße 126
79540 Lörrach
Germany
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
Medezin Sp. z o.o.
ul. Zbąszyńska 3
91-342 Łódź
CEFEA Sp. z o.o. Sp. komandytowa
ul. Działkowa 56
02-234 Warszawa
Pharma Innovations Sp. z o.o.
ul. Jagiellońska 76
03-301 Warszawa
Synoptis Industrial Sp. z o.o.
ul. Szosa Bydgoska 58
87-100 Toruń
CANPOLAND SPÓŁKA AKCYJNA
ul. Beskidzka 190
91-610 Łódź
Marketing authorization number in France, the country of export: 321 970-4
34009 321 970 4 0
554 435-4
34009 554 435 4 4
Parallel import authorization number: 161/22
Date of leaflet approval: 05.04.2022
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.